Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

In Reply.

Ke Y, Simard JN, Gonthier R, Martel C, Vaillancourt M, Portman D, Bélanger A, Labrie F.

Menopause. 2018 Aug;25(8):953-954. doi: 10.1097/GME.0000000000001147. No abstract available.

PMID:
29975286
2.

Concentration range of serum sex steroids in normal postmenopausal women and those with diagnosis of vulvovaginal atrophy.

Ke Y, Bélanger A, Simard JN, Gonthier R, Martel C, Vaillancourt M, Labrie F.

Menopause. 2018 Mar;25(3):293-300. doi: 10.1097/GME.0000000000000993.

PMID:
29206779
3.

To the Editor.

Bélanger A, Utian W.

Menopause. 2017 Aug;24(8):988. doi: 10.1097/GME.0000000000000939. No abstract available.

PMID:
28697044
4.

Androgens in women are essentially made from DHEA in each peripheral tissue according to intracrinology.

Labrie F, Martel C, Bélanger A, Pelletier G.

J Steroid Biochem Mol Biol. 2017 Apr;168:9-18. doi: 10.1016/j.jsbmb.2016.12.007. Epub 2017 Jan 30. Review.

PMID:
28153489
5.

Science of intracrinology in postmenopausal women.

Labrie F, Bélanger A, Pelletier G, Martel C, Archer DF, Utian WH.

Menopause. 2017 Jun;24(6):702-712. doi: 10.1097/GME.0000000000000808. Review.

PMID:
28098598
6.

Letter to the Editor: Superior Mass Spectrometry-Based Estrogen Assays Should Replace Immunoassays.

Labrie F, Ke Y, Gonthier R, Bélanger A.

J Clin Endocrinol Metab. 2015 Sep;100(9):L86-7. doi: 10.1210/jc.2015-2930. No abstract available.

PMID:
26339747
7.

Reprint of "Why both LC-MS/MS and FDA-compliant validation are essential for accurate estrogen assays?".

Labrie F, Ke Y, Gonthier R, Bélanger A.

J Steroid Biochem Mol Biol. 2015 Sep;153:54-6. doi: 10.1016/j.jsbmb.2015.08.017. Epub 2015 Aug 19. No abstract available.

PMID:
26291833
8.

Why both LC-MS/MS and FDA-compliant validation are essential for accurate estrogen assays?

Labrie F, Ke Y, Gonthier R, Bélanger A.

J Steroid Biochem Mol Biol. 2015 May;149:89-91. doi: 10.1016/j.jsbmb.2015.02.003. Epub 2015 Feb 9. No abstract available.

PMID:
25676471
9.

On "The American Physical Therapy Association's top five choosing wisely recommendations." White NT, Delitto A, Manal TJ, Miller S. Phys Ther. doi: 10.2522/ptj.20140287.

Belanger AY, Cameron MH, Michlovitz SL, Bellew JW, Freeman L.

Phys Ther. 2015 Jan;95(1):142-3. doi: 10.2522/ptj.2015.95.1.142. No abstract available.

PMID:
25554705
10.

Multiple roles for UDP-glucuronosyltransferase (UGT)2B15 and UGT2B17 enzymes in androgen metabolism and prostate cancer evolution.

Gauthier-Landry L, Bélanger A, Barbier O.

J Steroid Biochem Mol Biol. 2015 Jan;145:187-92. doi: 10.1016/j.jsbmb.2014.05.009. Epub 2014 May 23. Review.

PMID:
24861263
11.

Using microsimulation to reassess aging trends in Canada.

Légaré J, Décarie Y, Bélanger A.

Can J Aging. 2014 Jun;33(2):208-19. doi: 10.1017/S071498081400004X. Epub 2014 May 12.

PMID:
24813722
12.

Androgen glucuronidation: an unexpected target for androgen deprivation therapy, with prognosis and diagnostic implications.

Grosse L, Pâquet S, Caron P, Fazli L, Rennie PS, Bélanger A, Barbier O.

Cancer Res. 2013 Dec 1;73(23):6963-71. doi: 10.1158/0008-5472.CAN-13-1462. Epub 2013 Oct 11.

13.

Testosterone challenge and androgen receptor activity in relation to UGT2B17 genotypes.

Ekström L, Cevenini L, Michelini E, Schulze J, Thörngren JO, Belanger A, Guillemette C, Garle M, Roda A, Rane A.

Eur J Clin Invest. 2013 Mar;43(3):248-55. doi: 10.1111/eci.12037. Epub 2013 Jan 7.

PMID:
23294483
14.

Differential expression of the androgen-conjugating UGT2B15 and UGT2B17 enzymes in prostate tumor cells during cancer progression.

Pâquet S, Fazli L, Grosse L, Verreault M, Têtu B, Rennie PS, Bélanger A, Barbier O.

J Clin Endocrinol Metab. 2012 Mar;97(3):E428-32. doi: 10.1210/jc.2011-2064. Epub 2011 Dec 14.

PMID:
22170718
15.

Serum sex steroids measured in middle-aged European and African-Caribbean men by gas chromatography-mass spectrometry.

Giton F, Fiet J, Cornu JN, Cussenot O, Bélanger A, Urien S, Oliva A, Blanchet P, Multigner L.

Eur J Endocrinol. 2011 Dec;165(6):917-24. doi: 10.1530/EJE-11-0551. Epub 2011 Sep 27.

PMID:
21951700
16.

Correlation between circulatory, local prostatic, and intra-prostatic androgen levels.

Olsson M, Ekström L, Guillemette C, Belanger A, Rane A, Gustafsson O.

Prostate. 2011 Jun 15;71(9):909-14. doi: 10.1002/pros.21307. Epub 2010 Dec 6.

PMID:
21541968
17.

Bioavailability of testosterone enanthate dependent on genetic variation in the phosphodiesterase 7B but not on the uridine 5'-diphospho-glucuronosyltransferase (UGT2B17) gene.

Ekström L, Schulze JJ, Guillemette C, Belanger A, Rane A.

Pharmacogenet Genomics. 2011 Jun;21(6):325-32. doi: 10.1097/FPC.0b013e328344c5c6.

PMID:
21383644
18.

Profiling of endogenous estrogens, their precursors, and metabolites in endometrial cancer patients: association with risk and relationship to clinical characteristics.

Audet-Walsh E, Lépine J, Grégoire J, Plante M, Caron P, Têtu B, Ayotte P, Brisson J, Villeneuve L, Bélanger A, Guillemette C.

J Clin Endocrinol Metab. 2011 Feb;96(2):E330-9. doi: 10.1210/jc.2010-2050. Epub 2010 Dec 8.

PMID:
21147881
19.

Plasma estrone sulfate assay in men: Comparison of radioimmunoassay, mass spectrometry coupled to gas chromatography (GC-MS), and liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Giton F, Caron P, Bérubé R, Bélanger A, Barbier O, Fiet J.

Clin Chim Acta. 2010 Sep 6;411(17-18):1208-13. doi: 10.1016/j.cca.2010.04.022. Epub 2010 Apr 26.

20.

Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways.

Lépine J, Audet-Walsh E, Grégoire J, Têtu B, Plante M, Ménard V, Ayotte P, Brisson J, Caron P, Villeneuve L, Bélanger A, Guillemette C.

J Clin Endocrinol Metab. 2010 Jun;95(6):2689-98. doi: 10.1210/jc.2010-2648. Epub 2010 Apr 6.

PMID:
20371658
21.

Profiling endogenous serum estrogen and estrogen-glucuronides by liquid chromatography-tandem mass spectrometry.

Caron P, Audet-Walsh E, Lépine J, Bélanger A, Guillemette C.

Anal Chem. 2009 Dec 15;81(24):10143-8. doi: 10.1021/ac9019126.

PMID:
19916521
22.

The human UGT1A3 enzyme conjugates norursodeoxycholic acid into a C23-ester glucuronide in the liver.

Trottier J, El Husseini D, Perreault M, Pâquet S, Caron P, Bourassa S, Verreault M, Inaba TT, Poirier GG, Bélanger A, Guillemette C, Trauner M, Barbier O.

J Biol Chem. 2010 Jan 8;285(2):1113-21. doi: 10.1074/jbc.M109.073908. Epub 2009 Nov 4.

23.

Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer.

Labrie F, Cusan L, Gomez JL, Martel C, Bérubé R, Bélanger P, Bélanger A, Vandenput L, Mellström D, Ohlsson C.

J Steroid Biochem Mol Biol. 2009 Jan;113(1-2):52-6. doi: 10.1016/j.jsbmb.2008.11.004. Epub 2008 Nov 27.

PMID:
19073258
24.

Inactivation of androgens by UDP-glucuronosyltransferases in the human prostate.

Barbier O, Bélanger A.

Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):259-70. doi: 10.1016/j.beem.2008.01.001. Review.

PMID:
18471784
25.

Androgen biosynthetic pathways in the human prostate.

Luu-The V, Bélanger A, Labrie F.

Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):207-21. doi: 10.1016/j.beem.2008.01.008. Review.

PMID:
18471780
26.

Inactivation by UDP-glucuronosyltransferase enzymes: the end of androgen signaling.

Chouinard S, Yueh MF, Tukey RH, Giton F, Fiet J, Pelletier G, Barbier O, Bélanger A.

J Steroid Biochem Mol Biol. 2008 Apr;109(3-5):247-53. doi: 10.1016/j.jsbmb.2008.03.016. Epub 2008 Mar 13.

PMID:
18467088
27.

Calcitrol (1alpha,25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells.

Kaeding J, Bélanger J, Caron P, Verreault M, Bélanger A, Barbier O.

Mol Cancer Ther. 2008 Feb;7(2):380-90. doi: 10.1158/1535-7163.MCT-07-0455.

28.

Disruption of the ugt1 locus in mice resembles human Crigler-Najjar type I disease.

Nguyen N, Bonzo JA, Chen S, Chouinard S, Kelner MJ, Hardiman G, Bélanger A, Tukey RH.

J Biol Chem. 2008 Mar 21;283(12):7901-11. doi: 10.1074/jbc.M709244200. Epub 2008 Jan 7.

29.

Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells.

Kaeding J, Bouchaert E, Bélanger J, Caron P, Chouinard S, Verreault M, Larouche O, Pelletier G, Staels B, Bélanger A, Barbier O.

Biochem J. 2008 Mar 1;410(2):245-53.

PMID:
17988216
30.
31.
32.

The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men.

Swanson C, Mellström D, Lorentzon M, Vandenput L, Jakobsson J, Rane A, Karlsson M, Ljunggren O, Smith U, Eriksson AL, Bélanger A, Labrie F, Ohlsson C.

J Clin Endocrinol Metab. 2007 Dec;92(12):4878-82. Epub 2007 Aug 14.

PMID:
17698910
33.

Sex steroid levels and cortical bone size in young men are associated with a uridine diphosphate glucuronosyltransferase 2B7 polymorphism (H268Y).

Swanson C, Lorentzon M, Vandenput L, Labrie F, Rane A, Jakobsson J, Chouinard S, Bélanger A, Ohlsson C.

J Clin Endocrinol Metab. 2007 Sep;92(9):3697-704. Epub 2007 Jun 19.

PMID:
17579197
34.

A pharmacogenomics study of the human estrogen glucuronosyltransferase UGT1A3.

Caillier B, Lépine J, Tojcic J, Ménard V, Perusse L, Bélanger A, Barbier O, Guillemette C.

Pharmacogenet Genomics. 2007 Jul;17(7):481-95.

PMID:
17558304
35.

Reproducibility of serum sex steroid assays in men by RIA and mass spectrometry.

Hsing AW, Stanczyk FZ, Bélanger A, Schroeder P, Chang L, Falk RT, Fears TR.

Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):1004-8.

36.
37.

Metabolism of DHEA in postmenopausal women following percutaneous administration.

Labrie F, Bélanger A, Bélanger P, Bérubé R, Martel C, Cusan L, Gomez J, Candas B, Chaussade V, Castiel I, Deloche C, Leclaire J.

J Steroid Biochem Mol Biol. 2007 Feb;103(2):178-88. Epub 2006 Nov 3.

PMID:
17084625
38.

Immunohistochemical localization and biological activity of the steroidogenic enzyme cytochrome P450 17alpha-hydroxylase/C17, 20-lyase (P450C17) in the frog brain and pituitary.

Do Rego JL, Tremblay Y, Luu-The V, Repetto E, Castel H, Vallarino M, Bélanger A, Pelletier G, Vaudry H.

J Neurochem. 2007 Jan;100(1):251-68. Epub 2006 Oct 31.

39.
40.

Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women.

Labrie F, Bélanger A, Bélanger P, Bérubé R, Martel C, Cusan L, Gomez J, Candas B, Castiel I, Chaussade V, Deloche C, Leclaire J.

J Steroid Biochem Mol Biol. 2006 Jun;99(4-5):182-8. Epub 2006 Apr 18.

PMID:
16621522
41.

Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone.

Thibaudeau J, Lépine J, Tojcic J, Duguay Y, Pelletier G, Plante M, Brisson J, Têtu B, Jacob S, Perusse L, Bélanger A, Guillemette C.

Cancer Res. 2006 Jan 1;66(1):125-33.

42.

Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue.

Chouinard S, Tessier M, Vernouillet G, Gauthier S, Labrie F, Barbier O, Bélanger A.

Mol Pharmacol. 2006 Mar;69(3):908-20. Epub 2005 Dec 8.

PMID:
16339389
43.

Gonadotropin-releasing hormone agonists in the treatment of prostate cancer.

Labrie F, Bélanger A, Luu-The V, Labrie C, Simard J, Cusan L, Gomez J, Candas B.

Endocr Rev. 2005 May;26(3):361-79. Epub 2005 May 2. Review.

PMID:
15867098
44.

Major impact of hormonal therapy in localized prostate cancer--death can already be an exception.

Labrie F, Cusan L, Gomez J, Luu-The V, Candas B, Bélanger A, Labrie C.

J Steroid Biochem Mol Biol. 2004 Dec;92(5):327-44. Epub 2004 Dec 21. Review.

PMID:
15698538
45.

Cellular specific expression of the androgen-conjugating enzymes UGT2B15 and UGT2B17 in the human prostate epithelium.

Chouinard S, Pelletier G, Bélanger A, Barbier O.

Endocr Res. 2004 Nov;30(4):717-25.

PMID:
15666817
46.

Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: an overview.

Guillemette C, Bélanger A, Lépine J.

Breast Cancer Res. 2004;6(6):246-54. Epub 2004 Sep 27. Review.

47.

Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium.

Lépine J, Bernard O, Plante M, Têtu B, Pelletier G, Labrie F, Bélanger A, Guillemette C.

J Clin Endocrinol Metab. 2004 Oct;89(10):5222-32.

PMID:
15472229
48.

Plasma lipoprotein profile in the male cynomolgus monkey under normal, hypogonadal, and combined androgen blockade conditions.

Leblanc M, Bélanger MC, Julien P, Tchernof A, Labrie C, Bélanger A, Labrie F.

J Clin Endocrinol Metab. 2004 Apr;89(4):1849-57.

PMID:
15070955
49.

Loss and recovery of independence among seniors.

Martel L, Bélanger A, Berthelot JM.

Health Rep. 2002 Jul;13(4):35-48.

50.

Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial.

Labrie F, Candas B, Cusan L, Gomez JL, Bélanger A, Brousseau G, Chevrette E, Lévesque J.

Prostate. 2004 May 15;59(3):311-8.

PMID:
15042607

Supplemental Content

Loading ...
Support Center